News for GILEAD SCIENCES (GILDD.BA)

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Friday. Shares of Skechers U.S.A., Inc. SKX fell sharply in to...

Fewer Americans plan on taking a vacation this summer. Intel backs off plan to detach from Intel Capital. Guess? spikes on a report of a rival bid to acquire the company.

Shares of Coursera, Inc. COUR rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Cours...

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Philli...

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ETCompany ParticipantsJacquie Ross - SVP, Treasury &...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

As of midday Thursday, April 24, 2025, major U.S. stock indexes are extending their winning streak for a third consecutive session. The S&P 500 has added

As of midday Thursday, April 24, 2025, U.S. stock markets are extending their rally for the third consecutive day, with technology stocks leading the charge.

In the current market session, Gilead Sciences Inc. GILD share price is at $107.00, after a 1.41% increase. Moreover, over the past month, the stock decreased b...

Key Takeaways: Gilead Sciences (GILD) is scheduled to release its Q1 earnings on April 24th. Analysts predict an EPS of $1.74 and revenue of $6.78 billio

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an […]

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Gilead Sciences (GILD) reports successful Phase 3 trial results for Trodelvy® plus Keytruda® in metastatic triple-negative breast cancer. The combinat

Stock markets are facing significant pressure today as investors react to President Trump's criticism of the Federal Reserve and ongoing concerns about

First-quarter earnings season picks up speed inside our portfolio and outside of it.

With the policy overhang, earnings guidance will be closely watched during the second busiest week. Markets are likely to be dominated by earnings and tariff news.

Based on the search results, I now have enough information to create a comprehensive market recap article for April 18, 2025. I'll focus on the current market

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025